Lupus is an autoimmune disorder that affects half a billion of the population worldwide. Only a few details about the said disease are known. In fact, the main cause and cure for lupus is unknown. The said disease can infect a person out of nowhere and cause inflammation, tissue damage to blood vessels, organs, and skin. The possibility of being genetic related was not considered until the 1950s. After seven decades, two possible causes of it were discovered.
Immunologist Simon Jiang and his colleagues have found the major cause of lupus after six years of research. A pair of rare genetic mutations are behind the autoimmune disorder. The genetic abnormalities are said to drive the immune system to attack the body’s own tissue and are mostly found in a lupus patient.
ImmuPharma PLC (LON:IMM) is headquartered in London and has its research operations in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). ImmuPharma is dedicated to the development of innovative drugs to treat serious medical conditions, characterised by High unmet medical need,Low marketing costs and Relatively low development costs
